Recombinant activated factor VII: does it really save lives?

Abstract

Methods Using the experience of our institute and an Internet search. In one of the largest prospective, randomized, multicentric studies of rFVIIa, 301 patients with blunt/penetrating trauma were enrolled � of whom 277 patients at the end of study were analyzable. The trial included 399 patients, all diagnosed by CT scan within 3 hours of intracerebral hemorrhage onset. Patients were randomly assigned to receive placebo (n = 96), 40 �g/kg(n = 108), 80 �g/kg (n = 92), or 160 �g/kg (n = 103) doses of rFVIIa within 1 hour of the baseline scan.